Celgene will gain access to Juno’s pipeline of CAR-T cancer drugs, which are a novel class of therapies that genetically alter patients’ immune cells to attack cancer.
Celgene, which currently owns a 9.7 percent stake in Juno, will pay $87 a share for the rest of the company.
The deal is part of Celgene’s plan to help offset upcoming revenue loss as a result of competition. The drugmaker’s top-selling blood cancer drug, Revlimid, is expected to face competition in the upcoming years after its patent expires.
The transaction is expected to close in the first quarter of fiscal year 2018.
More articles on supply chain:
Google venture arm invests in company developing universal flu vaccine
Teva’s board of directors take 50 percent pay cut amid financial woes
Stanford Blood Center faces critical shortage of blood, notes the flu is keeping potential donors away
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.